Polikistik Over Sendromu ve Hiperandrojenizm: Etiyopatogenezden Güncel Klinik Yönetime
Özet
Referanslar
Teede HJ, et al. International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome 2023. Human Reproduction. 2023;38(9). (Global Konsensus Raporu)
Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592. (Halen gecerliliğini koruyan temel kılavuz)
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-2855. (Epidemiyolojik temel)
Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol. 2018;132(2):321-336.
Franik S, et al. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;(5):CD010287. (Letrozolun ustunluğunu kanıtlayan meta-analiz)
Lizneva D, et al. Phenotypes of Polycystic Ovary Syndrome: Implications for Management. Endocrinol Metab Clin North Am. 2021;50(1).
Dumesic DA, et al. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology,
and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015;36(5):487-525.
He Y, et al. El microbioma intestinal i la SOP: acoblament actiu del metabolisme i la immunitat de l’hoste. Nat Rev Endocrinol. 2024. (Teoria DOGMA)Zhao X, et al.
Nonobese young females with PCOS are at high risk for long-term cardiovascular disease. Eur J Prev Cardiol, 2025.
O’Reilly MW, et al. 11-Oxygenated C19 steroids are the predominant androgens in PCOS. JCEM, 2017.
Legro RS, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. NEJM, 2014. 11
Fraser GL, et al. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant.JCEM, 202
Referanslar
Teede HJ, et al. International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome 2023. Human Reproduction. 2023;38(9). (Global Konsensus Raporu)
Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592. (Halen gecerliliğini koruyan temel kılavuz)
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-2855. (Epidemiyolojik temel)
Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol. 2018;132(2):321-336.
Franik S, et al. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;(5):CD010287. (Letrozolun ustunluğunu kanıtlayan meta-analiz)
Lizneva D, et al. Phenotypes of Polycystic Ovary Syndrome: Implications for Management. Endocrinol Metab Clin North Am. 2021;50(1).
Dumesic DA, et al. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology,
and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015;36(5):487-525.
He Y, et al. El microbioma intestinal i la SOP: acoblament actiu del metabolisme i la immunitat de l’hoste. Nat Rev Endocrinol. 2024. (Teoria DOGMA)Zhao X, et al.
Nonobese young females with PCOS are at high risk for long-term cardiovascular disease. Eur J Prev Cardiol, 2025.
O’Reilly MW, et al. 11-Oxygenated C19 steroids are the predominant androgens in PCOS. JCEM, 2017.
Legro RS, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. NEJM, 2014. 11
Fraser GL, et al. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant.JCEM, 202
